Stock listing
Stuttgart:LUP Luye Pharma Group Ltd. Aktie
German listing (Stuttgart) of Luye Pharma Group Ltd. · home listing HKEX:2186
Follow Luye Pharma Group Ltd. into a list and get an email when it puts out news.
Home listing price · HKEX:2186
$1.48 HKD -0.06 (-4.2%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, HKEX:2186
- Day range
- $1.38 – $1.48 HKDNov 20, 2026
- Volume
- 51.54M sharesNov 20, 2026
- Market cap
- $5.89B HKDAt the close on Nov 20, 2026 · price × 3.99B shares outstanding
- 52-week range
- $1.38 – $3.22 HKDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $51.95M HKDMedian day 23.76M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| HKEX:2186 · Home | $1.475 HKD | -0.065 (-4.2%) | 51,541,458 | $1.41 | $1.48 | $1.38 | $1.54 | Close on Nov 20, 2026 |
| Frankfurt:LUP | €0.162 EUR | -0.004 (-2.4%) | — | €0.162 | €0.162 | €0.162 | €0.166 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · HKEX:2186 · HKD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.475 | -0.065 | -4.2% | $1.41 | $1.48 | $1.38 | 51,541,458 | |
| $1.54 | +0.005 | +0.3% | $1.55 | $1.55 | $1.505 | 21,007,500 | |
| $1.535 | -0.01 | -0.6% | $1.54 | $1.555 | $1.51 | 23,934,500 | |
| $1.545 | -0.025 | -1.6% | $1.58 | $1.58 | $1.535 | 23,747,542 | |
| $1.57 | -0.065 | -4.0% | $1.615 | $1.635 | $1.565 | 23,052,000 | |
| $1.635 | -0.05 | -3.0% | $1.685 | $1.685 | $1.62 | 33,356,500 | |
| $1.685 | +0.005 | +0.3% | $1.655 | $1.685 | $1.655 | 13,532,500 | |
| $1.68 | +0.01 | +0.6% | $1.69 | $1.70 | $1.665 | 13,744,000 | |
| $1.67 | -0.005 | -0.3% | $1.685 | $1.725 | $1.66 | 11,890,000 | |
| $1.675 | -0.015 | -0.9% | $1.63 | $1.69 | $1.625 | 16,528,500 | |
| $1.69 | +0.07 | +4.3% | $1.62 | $1.695 | $1.62 | 42,709,000 | |
| $1.62 | +0.015 | +0.9% | $1.605 | $1.63 | $1.575 | 28,410,500 | |
| $1.605 | 0.00 | 0.0% | $1.61 | $1.625 | $1.575 | 19,672,500 | |
| $1.605 | +0.02 | +1.3% | $1.59 | $1.625 | $1.565 | 17,222,500 | |
| $1.585 | +0.015 | +1.0% | $1.565 | $1.60 | $1.545 | 19,156,000 | |
| $1.57 | -0.035 | -2.2% | $1.605 | $1.615 | $1.565 | 23,780,500 | |
| $1.605 | +0.01 | +0.6% | $1.60 | $1.61 | $1.585 | 15,199,500 | |
| $1.595 | -0.01 | -0.6% | $1.605 | $1.615 | $1.58 | 16,427,664 | |
| $1.605 | +0.015 | +0.9% | $1.595 | $1.61 | $1.57 | 16,548,000 | |
| $1.59 | +0.01 | +0.6% | $1.585 | $1.60 | $1.55 | 36,948,000 | |
| $1.58 | -0.115 | -6.8% | $1.695 | $1.695 | $1.58 | 38,823,500 | |
| $1.695 | +0.01 | +0.6% | $1.70 | $1.715 | $1.68 | 15,331,500 | |
| $1.685 | -0.02 | -1.2% | $1.705 | $1.715 | $1.675 | 19,741,500 | |
| $1.705 | -0.015 | -0.9% | $1.72 | $1.755 | $1.685 | 30,872,002 | |
| $1.72 | +0.02 | +1.2% | $1.70 | $1.72 | $1.67 | 20,816,000 | |
| $1.70 | -0.01 | -0.6% | $1.72 | $1.72 | $1.68 | 11,492,798 | |
| $1.71 | -0.01 | -0.6% | $1.72 | $1.72 | $1.655 | 25,305,500 | |
| $1.72 | -0.01 | -0.6% | $1.745 | $1.755 | $1.705 | 14,568,000 | |
| $1.73 | -0.035 | -2.0% | $1.775 | $1.78 | $1.725 | 29,590,500 | |
| $1.765 | -0.025 | -1.4% | $1.835 | $1.855 | $1.765 | 31,632,000 | |
| $1.79 | -0.05 | -2.7% | $1.865 | $1.865 | $1.785 | 3,510,000 | |
| $1.84 | +0.035 | +1.9% | $1.815 | $1.845 | $1.815 | 2,134,000 | |
| $1.805 | -0.025 | -1.4% | $1.72 | $1.82 | $1.72 | 2,481,000 | |
| $1.83 | -0.065 | -3.4% | $1.89 | $1.89 | $1.78 | 8,243,000 | |
| $1.895 | +0.07 | +3.8% | $1.815 | $1.895 | $1.815 | 23,191,000 | |
| $1.825 | +0.04 | +2.2% | $1.795 | $1.835 | $1.785 | 16,376,000 | |
| $1.785 | -0.05 | -2.7% | $1.86 | $1.905 | $1.77 | 35,568,000 | |
| $1.835 | -0.05 | -2.7% | $1.89 | $1.90 | $1.82 | 2,611,500 | |
| $1.885 | -0.025 | -1.3% | $1.91 | $1.945 | $1.865 | 24,507,500 | |
| $1.91 | +0.07 | +3.8% | $1.845 | $1.92 | $1.825 | 32,407,500 | |
| $1.84 | -0.035 | -1.9% | $1.88 | $1.88 | $1.815 | 27,272,000 | |
| $1.875 | +0.125 | +7.1% | $1.775 | $1.925 | $1.755 | 81,285,922 | |
| $1.75 | +0.05 | +2.9% | $1.72 | $1.77 | $1.705 | 46,735,855 | |
| $1.70 | -0.065 | -3.7% | $1.76 | $1.76 | $1.69 | 52,330,473 | |
| $1.765 | -0.03 | -1.7% | $1.795 | $1.795 | $1.745 | 34,259,500 | |
| $1.795 | +0.005 | +0.3% | $1.79 | $1.81 | $1.77 | 11,242,000 | |
| $1.79 | -0.01 | -0.6% | $1.79 | $1.83 | $1.77 | 20,816,000 | |
| $1.80 | -0.03 | -1.6% | $1.82 | $1.82 | $1.79 | 16,109,500 | |
| $1.83 | -0.035 | -1.9% | $1.86 | $1.86 | $1.80 | 29,025,500 | |
| $1.865 | -0.055 | -2.9% | $1.915 | $1.915 | $1.85 | 23,020,000 | |
| $1.92 | +0.035 | +1.9% | $1.89 | $1.925 | $1.865 | 14,177,500 | |
| $1.885 | -0.01 | -0.5% | $1.89 | $1.905 | $1.855 | 24,612,000 | |
| $1.895 | +0.02 | +1.1% | $1.895 | $1.91 | $1.865 | 18,418,500 | |
| $1.875 | +0.03 | +1.6% | $1.845 | $1.90 | $1.845 | 26,557,500 | |
| $1.845 | -0.055 | -2.9% | $1.90 | $1.91 | $1.835 | 29,449,500 | |
| $1.90 | -0.04 | -2.1% | $1.94 | $1.95 | $1.88 | 42,259,500 | |
| $1.94 | -0.19 | -8.9% | $2.125 | $2.125 | $1.875 | 104,662,000 | |
| $2.13 | -0.015 | -0.7% | $2.145 | $2.195 | $2.095 | 34,007,500 | |
| $2.145 | -0.025 | -1.2% | $2.17 | $2.22 | $2.085 | 64,106,000 | |
| $2.17 | +0.02 | +0.9% | $2.17 | $2.23 | $2.155 | 30,129,639 | |
| $2.15 | +0.045 | +2.1% | $2.105 | $2.185 | $2.095 | 18,779,500 | |
| $2.105 | -0.055 | -2.5% | $2.17 | $2.17 | $2.09 | 28,617,500 | |
| $2.16 | +0.015 | +0.7% | $2.21 | $2.315 | $2.15 | 88,265,508 | |
| $2.145 | +0.155 | +7.8% | $2.04 | $2.185 | $2.03 | 100,124,031 |
- Ticker
- Stuttgart:LUP
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Stuttgart
- Currency
- EUR
What changed lately
Latest news release · Nov 19, 2026
Voluntary announcement approval of the group's innovative drug Ruoxinlin in China for the new indication of generalized anxiety disorder
Latest news
Voluntary announcement approval of the group's innovative drug Ruoxinlin in China for the new indication of generalized anxiety disorder
Nov 19, 2026
Closed $1.48 (-4.2%) on Nov 20, 2026
Voluntary announcement approval obtained for the group's innovative drug LY03021 for clinical trials in the U.S.
Nov 16, 2026
Closed $1.54 (-0.6%) on Nov 17, 2026
Voluntary announcement renewed inclusion of the group's innovative antidepressant Ruoxinlin in China's 2026 national reimbursement drug list
Nov 15, 2026
Closed $1.55 (-1.6%) on Nov 16, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
Nov 5, 2026
Closed $1.68 (-0.9%) on Nov 6, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Oct 7, 2026
Closed $1.77 (-1.4%) on Oct 8, 2026
Interim Report 2026
Sep 29, 2026
Closed $1.90 (+3.8%) on Sep 30, 2026
Luye Pharma Announces 2026 Interim Results
Sep 1, 2026
Closed $1.85 (-2.9%) on Sep 2, 2026
Luye Pharma Announces Successful Completion of a U.S. Bridging Clinical Trial of Its Innovative Drug LY03015 (VMAT2 Inhibitor/Sigma-1R...
Aug 5, 2026
Closed $2.07 (0.0%) on Aug 6, 2026
Luye Pharma Announces Positive Phase 2 Results of LY03015, a VMAT2 Inhibitor and Sigma-1R Agonist, for Tardive Dyskinesia in China
Jun 16, 2026
Closed $1.97 (+7.7%) on Jun 17, 2026
Luye Pharma Announces First Subject Enrolled in U.S. PK Bridging Clinical Trial of Its VMAT2 Inhibitor/Sigma-1R Agonist LY03015
Apr 21, 2026
Closed $2.82 (0.0%) on Apr 21, 2026
Luye Pharma Group Ltd. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 13 in the last 12 months · 35 in all · newest Nov 19, 2026 · oldest 2023
Where Luye Pharma Group Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| HKEX:2186 綠葉製藥 · Home listing | HKEX | Hong Kong | HKD |
| OTC:LYPHF | OTC | United States | USD |
| gettex:LUP | gettex | Germany | EUR |
| LS Exchange:A116Z9 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A116Z9 | Lang & Schwarz | Germany | EUR |
| Frankfurt:LUP | Frankfurt | Germany | EUR |
| Dusseldorf:LUP | Dusseldorf | Germany | EUR |
| Munich:LUP | Munich | Germany | EUR |
| Stuttgart:LUP · This page | Stuttgart | Germany | EUR |
Valuation
P/E 8.1× against a median of 22.2×: the lowest of 6 Pharmaceuticals companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $7.99B HKD
- P/E
- 8.1×
- EV/sales
- 1.1×
- EV/EBITDA
- 3.3×
- Price/book
- 0.3×
- Gross margin
- 66.0%
- Operating margin
- 19.7%
- Net margin
- 9.8%
- Debt to equity
- 0.8×
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Luye Pharma Group Ltd. · HKEX:2186 | US$751.7M | US$1.02B | 8.1× | 1.1× | 3.3× | 0.3× | 9.8% | 0.8× | n/a |
| Zhejiang Ausun Pharmaceutical Co., Ltd. Class A · SSE:603229 | US$780.2M | US$640.1M | n/a | 5.6× | n/a | 2.3× | −0.6% | 0.0× | n/a |
| Jinghua Pharmaceutical Group Co., Ltd. Class A · SZSE:002349 | US$774.6M | US$606.2M | 22.2× | 2.7× | n/a | 1.8× | 15.7% | 0.0× | n/a |
| Dezhan Healthcare Co., Ltd. Class A · SZSE:000813 | US$768.0M | US$680.7M | n/a | 13.0× | n/a | 1.1× | −111.1% | 0.0× | n/a |
| Knight Therapeutics, Inc. · TSX:GUD | US$763.1M | US$683.3M | 68.5× | 1.7× | 10.5× | 1.4× | 2.8% | 0.0× | 0.33 |
| Guizhou Bailing Group Pharmaceutical Co., Ltd. Class A · SZSE:002424 | US$757.0M | US$728.7M | n/a | 2.1× | n/a | 1.6× | −5.5% | 0.0× | n/a |
| Ardelyx, Inc. · NASDAQ:ARDX | US$751.6M | US$718.6M | n/a | 1.5× | n/a | 4.6× | −11.8% | 1.5× | 0.88 |
| Genomma Lab Internacional SAB de CV Class B · BMV:LAB/B | US$740.5M | US$953.0M | 8.3× | 1.1× | 4.8× | 1.2× | 10.0% | 0.6× | n/a |
| Bliss GVS Pharma Limited · NSE:BLISSGVS | US$735.1M | US$716.7M | 42.3× | 6.2× | 28.1× | 5.3× | 15.0% | 0.0× | n/a |
| Hunan Fangsheng Pharmaceutical Co., Ltd. Class A · SSE:603998 | US$732.2M | US$694.9M | 14.9× | 2.5× | n/a | 2.7× | 17.4% | 0.0× | n/a |
| Wanbangde Pharmaceutical Holding Group Co., Ltd. Class A · SZSE:002082 | US$729.9M | US$658.8M | n/a | 5.0× | n/a | 1.9× | −20.2% | 0.1× | n/a |
| Median of the others | US$754.3M | US$689.1M | 22.2× | 2.6× | 10.5× | 1.9× | 1.1% | 0.0× | 0.61 |
Forecasts
Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.
- Price target
- 2.83 HKD · Analysts' mean
- EPS, year to Dec 2026
- 0.17 · 2 analysts
- Revenue, year to Dec 2026
- 6.16B · 2 analysts
Events
| Quarter | Results | Share move |
|---|---|---|
| Q2 2025 | Aug 28, 2025 | +3.8% |
| Quarter to Mar 31, 2025 | Apr 29, 2025 | +1.0% |
| Q4 2024 | Mar 30, 2025 | −13.3% |
| Quarter to Sep 30, 2024 | Nov 18, 2024 | −1.9% |
| Q2 2024 | Aug 28, 2024 | +5.2% |
| Quarter to Mar 31, 2024 | May 29, 2024 | −2.2% |
| Q4 2023 | Mar 27, 2024 · Before open | 0.0% |
| Quarter to Sep 30, 2023 | Nov 8, 2023 | −1.3% |
| Q2 2023 | Aug 29, 2023 · Before open | +0.3% |
| Q1 2023 | May 31, 2023 | −0.3% |
All 19 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2022 | Mar 29, 2023 · Before open | +2.9% |
| Q3 2022 | Nov 9, 2022 | −0.9% |
| Q2 2022 | Aug 29, 2022 · Before open | 0.0% |
| Q1 2022 | Jun 1, 2022 | −4.9% |
| Q4 2021 | Mar 29, 2022 · After close | −4.4% |
| Q3 2021 | Nov 10, 2021 | +3.0% |
| Q2 2021 | Aug 29, 2021 · Before open | +4.3% |
| Q1 2021 | Jun 2, 2021 | −2.8% |
| Q4 2020 | Mar 31, 2021 · Before open | −1.6% |
Financials
Annual, in CNY
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.31B | 6.06B | 6.14B | 5.98B | 5.20B | 5.54B | 6.36B | 5.17B | 3.81B | 2.92B |
| Cost of revenue | 2.15B | 2.02B | 1.94B | 1.84B | 1.80B | 1.55B | 1.48B | 1.12B | 851.5M | 535.0M |
| Gross profit | 4.16B | 4.04B | 4.20B | 4.14B | 3.40B | 3.99B | 4.88B | 4.05B | 2.96B | 2.38B |
| Research and development | 413.9M | 498.6M | 586.2M | 857.3M | 683.2M | 789.9M | 579.5M | 491.2M | 288.7M | 193.7M |
| Selling, general and administrative | 679.6M | 582.0M | 644.0M | 582.9M | 570.8M | 521.5M | 525.9M | 441.4M | 431.6M | 267.0M |
| Operating income | 1.24B | 1.15B | 917.9M | 880.6M | 438.0M | 1.02B | 1.99B | 1.52B | 1.09B | 1.20B |
| Depreciation and amortization | 839.5M | 790.7M | 701.9M | 671.3M | 582.0M | 510.9M | 442.0M | 317.2M | 249.8M | 140.9M |
| EBITDA | 2.08B | 1.94B | 1.62B | 1.55B | 1.02B | 1.53B | 2.43B | 1.83B | 1.34B | 1.34B |
| Interest expense | 686.6M | 561.8M | 675.5M | 471.8M | 399.5M | 424.0M | 274.6M | 170.6M | 50.4M | 30.4M |
| Income before tax | 944.6M | 839.2M | 700.1M | 669.8M | -74.6M | 942.2M | 1.77B | 1.47B | 1.12B | 974.7M |
| Income tax | 239.0M | 194.2M | 161.0M | 86.5M | 70.2M | 238.9M | 279.8M | 167.5M | 135.8M | 80.7M |
| Net income | 618.7M | 471.9M | 532.6M | 604.8M | -134.4M | 706.6M | 1.47B | 1.30B | 981.4M | 891.5M |
| Earnings per share, basic | 0.16 | 0.13 | 0.14 | 0.17 | -0.04 | 0.23 | 0.47 | 0.40 | 0.30 | 0.27 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 4.50B | 4.94B | 3.24B | 2.32B | 2.44B | 3.87B | 2.33B | 1.67B | 1.27B | 397.8M |
| Short-term investments | 4.38B | 62.0M | 1.27B | 3.22B | 3.07B | 1.54B | 2.86B | 3.19B | 2.58B | 2.35B |
| Receivables | 3.26B | 4.30B | 2.35B | 1.78B | 1.77B | 1.81B | 1.83B | 1.63B | 1.41B | 1.55B |
| Inventory | 956.9M | 911.9M | 827.9M | 772.9M | 746.3M | 612.3M | 614.6M | 585.6M | 420.4M | 452.7M |
| Current assets | 15.2B | 13.3B | 10.7B | 10.8B | 10.4B | 9.97B | 9.36B | 8.68B | 6.30B | 5.28B |
| Property, plant and equipment | 6.06B | 6.05B | 5.15B | 4.59B | 4.20B | 4.02B | 3.42B | 2.84B | 2.01B | 1.70B |
| Goodwill | 1.08B | 1.01B | 1.04B | 1.00B | 985.4M | 1.06B | 1.04B | 1.04B | 1.04B | 995.9M |
| Total assets | 32.8B | 29.6B | 25.5B | 24.2B | 22.6B | 20.6B | 19.3B | 17.5B | 10.8B | 9.21B |
| Accounts payable | 1.15B | 689.3M | 767.2M | 559.9M | 570.9M | 485.3M | 298.5M | 279.8M | 104.6M | 116.1M |
| Current liabilities | 9.94B | 10.8B | 8.14B | 9.49B | 7.33B | 7.23B | 5.55B | 8.20B | 3.65B | 2.37B |
| Long-term debt | 3.59B | 2.69B | 3.18B | 2.24B | 4.21B | 4.33B | 4.50B | 847.5M | 232.0K | 0 |
| Total debt | 9.42B | 10.3B | 8.42B | 9.10B | 9.49B | 9.97B | 7.37B | 4.04B | 2.86B | 2.35B |
| Total liabilities | 14.2B | 13.9B | 12.0B | 13.2B | 13.5B | 12.5B | 9.94B | 9.60B | 3.86B | 2.64B |
| Shareholders' equity | 16.1B | 14.2B | 12.5B | 10.2B | 8.49B | 7.89B | 8.83B | 7.81B | 6.77B | 6.43B |
| Shares outstanding | 3.90B | 3.76B | 3.73B | 3.48B | 3.45B | 3.14B | 3.16B | 3.27B | 3.26B | 3.32B |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1.78B | 167.8M | 1.60B | 1.65B | 182.4M | 1.03B | 1.74B | 1.05B | 964.1M | 592.0M |
| Capital spending | -1.00B | -1.71B | -1.17B | -1.16B | -1.54B | -1.52B | -3.22B | -2.48B | -625.2M | -319.1M |
| Free cash flow | 780.4M | -1.54B | 430.2M | 490.1M | -1.36B | -486.4M | -1.48B | -1.44B | 338.9M | 272.9M |
| Cash from investing | -3.99B | -1.47B | -1.42B | -1.66B | -3.44B | 138.2M | -2.69B | -3.00B | -743.7M | -1.83B |
| Cash from financing | 1.79B | 2.96B | 841.6M | 54.1M | 1.88B | 254.0M | 1.61B | 2.40B | 732.6M | 820.0M |
| Dividends paid | 0 | -175.5M | -376.8M | -289.7M | -212.6M | -107.0M | ||||
| Share buybacks | 229.5M | 923.0M | 0 | 1.04B | -78.0M | -8.78M | -21.6M | -178.1M | 2.71M | |
| Change in cash | -445.6M | 1.70B | 915.2M | -114.5M | -1.43B | 1.54B | 652.6M | 407.0M | 868.1M | -445.9M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| VOLUNTARY ANNOUNCEMENT APPROVAL OF THE GROUP'S INNOVATIVE DRUG RUOXINLIN IN CHINA FOR THE NEW INDICATION OF GENERALIZED ANXIETY DISORDER | Nov 19, 2026 | Operations update | HKEX |
| VOLUNTARY ANNOUNCEMENT APPROVAL OBTAINED FOR THE GROUP'S INNOVATIVE DRUG LY03021 FOR CLINICAL TRIALS IN THE U.S. | Nov 16, 2026 | Other filings | HKEX |
| VOLUNTARY ANNOUNCEMENT RENEWED INCLUSION OF THE GROUP'S INNOVATIVE ANTIDEPRESSANT RUOXINLIN IN CHINA'S 2026 NATIONAL REIMBURSEMENT DRUG LIST | Nov 15, 2026 | Other filings | HKEX |
| Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026 | Nov 5, 2026 | Monthly return | HKEX |
| Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026 | Oct 7, 2026 | Monthly return | HKEX |
| Interim Report 2026 | Sep 29, 2026 | Interim report | HKEX |
Cap table
Built by 6ix from Luye Pharma Group Ltd.’s releases
- Common shares
- 3,994,515,953
- Fully diluted
- 3,994,515,953
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 3,994,515,953 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 3,994,515,953 |
Log in to ask 6ix AI your own questions about Luye Pharma Group Ltd.